메뉴 건너뛰기




Volumn 33, Issue 6, 2010, Pages 630-638

Immunogenicity for CD8 + and CD4 + T cells of 2 formulations of an incomplete Freund's adjuvant for multipeptide melanoma vaccines

Author keywords

Adjuvants; Cancer vaccines; CD4+ T cells; CD8+ T cells; Peptides; T cells

Indexed keywords

FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA DR ANTIGEN; MELANOMA VACCINE; MONTANIDE ISA 51; OLEIC ACID; PEPTIDE VACCINE;

EID: 77954960118     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181e311ac     Document Type: Article
Times cited : (22)

References (21)
  • 1
    • 77954956519 scopus 로고    scopus 로고
    • Montanide ISA 51 VG as Adjuvant for Human Vaccines
    • Bonhoure F, Gaucheron J. Montanide ISA 51 VG as Adjuvant for Human Vaccines. J Immunother. 2006;29:647-648.
    • (2006) J. Immunother. , vol.29 , pp. 647-648
    • Bonhoure, F.1    Gaucheron, J.2
  • 2
    • 0034793424 scopus 로고    scopus 로고
    • Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes
    • Slingluff CL Jr, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7:3012-3024.
    • (2001) Clin. Cancer Res. , vol.7 , pp. 3012-3024
    • Slingluff Jr., C.L.1    Yamshchikov, G.2    Neese, P.3
  • 3
    • 20044373641 scopus 로고    scopus 로고
    • MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma
    • Chianese-Bullock KA, Pressley J, Garbee C, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J IImmunol. 2005;174:3080-3086.
    • (2005) J. IImmunol , vol.174 , pp. 3080-3086
    • Chianese-Bullock, K.A.1    Pressley, J.2    Garbee, C.3
  • 4
    • 58149288270 scopus 로고    scopus 로고
    • Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines
    • Slingluff CL Jr, Yamshchikov GV, Hogan KT, et al. Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Ann Surg Oncol. 2008;15:3538-3549.
    • (2008) Ann. Surg. Oncol. , vol.15 , pp. 3538-3549
    • Slingluff Jr., C.L.1    Yamshchikov, G.V.2    Hogan, K.T.3
  • 5
    • 54449097809 scopus 로고    scopus 로고
    • Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens
    • Slingluff CL Jr, Petroni GR, Olson W, et al. Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008;26:4973-4980.
    • (2008) J. Clin. Oncol. , vol.26 , pp. 4973-4980
    • Slingluff Jr., C.L.1    Petroni, G.R.2    Olson, W.3
  • 6
    • 72549116845 scopus 로고    scopus 로고
    • + T cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial
    • + T cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial. Clin Cancer Res. 2009;15:7036-7044.
    • (2009) Clin. Cancer Res. , vol.15 , pp. 7036-7044
    • Slingluff Jr., C.L.1    Petroni, G.R.2    Olson, W.C.3
  • 7
    • 42649117473 scopus 로고    scopus 로고
    • A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
    • Chianese-Bullock KA, Irvin WP Jr, Petroni GR, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother. 2008;31:420-430.
    • (2008) J. Immunother. , vol.31 , pp. 420-430
    • Chianese-Bullock, K.A.1    Irvin Jr., W.P.2    Petroni, G.R.3
  • 8
    • 35948972459 scopus 로고    scopus 로고
    • Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting
    • Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res. 2007;13:6386-6395.
    • (2007) Clin. Cancer Res. , vol.13 , pp. 6386-6395
    • Slingluff Jr., C.L.1    Petroni, G.R.2    Chianese-Bullock, K.A.3
  • 9
    • 14044259609 scopus 로고    scopus 로고
    • Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule
    • Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22:4474-4485.
    • (2004) J. Clin. Oncol. , vol.22 , pp. 4474-4485
    • Slingluff Jr., C.L.1    Petroni, G.R.2    Yamshchikov, G.V.3
  • 10
    • 0642311904 scopus 로고    scopus 로고
    • Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells
    • Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016-4026.
    • (2003) J. Clin. Oncol. , vol.21 , pp. 4016-4026
    • Slingluff Jr., C.L.1    Petroni, G.R.2    Yamshchikov, G.V.3
  • 11
    • 77954956955 scopus 로고    scopus 로고
    • + T cell responses: Outcome of a multicenter randomized trial [abstract]
    • Abstract #3008, ASCO annual meeting, Orlando, FL
    • + T cell responses: outcome of a multicenter randomized trial [abstract]. J Clin Oncol (Meeting Abstracts) 2009;27: Abstract #3008, ASCO annual meeting, Orlando, FL.
    • (2009) J. Clin. Oncol. (Meeting Abstracts) , vol.27
    • Slingluff Jr., C.L.1    Petroni, G.R.2    Olson, W.C.3
  • 12
    • 77954958474 scopus 로고    scopus 로고
    • Effects of melanoma-derived helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine [abstract]
    • Slingluff C, Petroni G, Chianese-Bullock K, et al. Effects of melanoma-derived helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine [abstract]. J Immunother. 2009;32:976.
    • (2009) J. Immunother. , vol.32 , pp. 976
    • Slingluff, C.1    Petroni, G.2    Chianese-Bullock, K.3
  • 13
    • 13744260910 scopus 로고    scopus 로고
    • Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members
    • Hogan KT, Sutton JN, Chu KU, et al. Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunol Immunother. 2005;54:359-371.
    • (2005) Cancer Immunol. Immunother. , vol.54 , pp. 359-371
    • Hogan, K.T.1    Sutton, J.N.2    Chu, K.U.3
  • 14
    • 0033102344 scopus 로고    scopus 로고
    • Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development [published erratum appears in
    • Kittlesen DJ, Thompson LW, Gulden PH, et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development [published erratum appears in J Immunol 1999;162:3106].
    • (1999) J. Immunol. , vol.162 , pp. 3106
    • Kittlesen, D.J.1    Thompson, L.W.2    Gulden, P.H.3
  • 15
    • 0032030641 scopus 로고    scopus 로고
    • J Immunother. 1998;160:2099-2106.
    • (1998) J. Immunother. , vol.160 , pp. 2099-2106
  • 17
    • 70350135349 scopus 로고    scopus 로고
    • A phase III multi-institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma [abstract]
    • abstract CRA9011
    • Schwartzentruber DJ, Lawson D, Richards J, et al. A phase III multi-institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma [abstract]. J Clin Oncol (Meeting Abstracts). 2009;27: abstract CRA9011.
    • (2009) J. Clin. Oncol. (Meeting Abstracts) , vol.27
    • Schwartzentruber, D.J.1    Lawson, D.2    Richards, J.3
  • 18
    • 33646779561 scopus 로고    scopus 로고
    • Altered CD8 (+) T-cell responses when immunizing with multiepitope peptide vaccines
    • Rosenberg SA, Sherry RM, Morton KE, et al. Altered CD8 (+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother. 2006;29:224-231.
    • (2006) J. Immunother. , vol.29 , pp. 224-231
    • Rosenberg, S.A.1    Sherry, R.M.2    Morton, K.E.3
  • 19
    • 60849091328 scopus 로고    scopus 로고
    • Multipeptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies
    • Chianese-Bullock KA, Lewis ST, Sherman NE, et al. Multipeptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine. 2009;27:1764-1770.
    • (2009) Vaccine , vol.27 , pp. 1764-1770
    • Chianese-Bullock, K.A.1    Lewis, S.T.2    Sherman, N.E.3
  • 20
    • 77954951870 scopus 로고    scopus 로고
    • The melanoma vaccine microenvironment: Do negative contributors of immune function compartmentalize the vaccine site? [abstract]
    • Schaefer J, Deacon D, Smolkin M, et al. The melanoma vaccine microenvironment: do negative contributors of immune function compartmentalize the vaccine site? [abstract]. J Immunother. 2009;32:975-976.
    • (2009) J. Immunother. , vol.32 , pp. 975-976
    • Schaefer, J.1    Deacon, D.2    Smolkin, M.3
  • 21
    • 77954951500 scopus 로고    scopus 로고
    • Peptide/incomplete Freund adjuvant emulsion depots are a graveyard for tumor antigen-specific CD8+ T cells [abstract]
    • Overwijk W, Hailemichael Y, Dai Z, et al. Peptide/incomplete Freund adjuvant emulsion depots are a graveyard for tumor antigen-specific CD8+ T cells [abstract]. J Immunother. 2009;32:971.
    • (2009) J. Immunother. , vol.32 , pp. 971
    • Overwijk, W.1    Hailemichael, Y.2    Dai, Z.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.